Article
Small-molecule inhibition of MAP2K4 is synergistic with RAS inhibitors in KRAS-mutant cancers.
Proceedings of the National Academy of Sciences of the United States of America - 27 Feb 2024
Jansen Robin A, Mainardi Sara, Dias Matheus Henrique, Bosma Astrid, van Dijk Emma, Selig Roland, Albrecht Wolfgang, Laufer Stefan A, Zender Lars, Bernards René
Abstract excerpt
The Kirsten rat sarcoma viral oncogene homologue KRAS is among the most commonly mutated oncogenes in human cancers, thus representing an attractive target for precision oncology. The approval for clinical use of the first selective inhibitors of G12C mutant KRAS therefore holds great promise for cancer treatment. However, despite initial encouraging clinical results, the overall survival benefit that patients...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.